Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsTranslating TrialsCase-Based Peer PerspectivesPodcastsVideosShorts
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Linda Wenger, LUNGevity Foundation

Advertisement

Articles by Linda Wenger, LUNGevity Foundation

LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients

ByLinda Wenger, LUNGevity Foundation
June 20th 2018

Key recommendations from LUNGevity's Expanded Eligibility working group were published in the Journal of Thoracic Oncology.

Advertisement

Latest Updated Articles

  • LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients
    LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients

    June 20th 2018



Advertisement
Advertisement

Trending on Oncology Nursing News

1

FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer

2

Thoracic Oncology Advances and Toxicity Management

3

First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC

4

SBRT Reduces Bowel Toxicity in Localized Intermediate-Risk Prostate Cancer

5

FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us